ClinicalTrials.gg
RecruitingNCT07543796TRD205Updated Apr 22, 2026

Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb)

A Phase 2 interventional study of TRD205 Tablets, oral; 400 mg initial dose, then 200 mg q12h for 3 doses; total 4 doses and TRD205 Tablets, oral; 800 mg initial dose, then 400 mg q12h; total 4 doses in Postoperative Analgesia After Unilateral Hip Arthroplasty, sponsored by Beijing Tide Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Beijing Tide Pharmaceutical Co., Ltd (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a phase IIa, multicenter ,randomized, double-blind, Double-Dummy, Active- and placebo-controlled study designed to evaluate the efficacy, safety and kinetic characteristics of TRD205 tablets for postoperative analgesia after unilateral hip arthroplasty

Read the detailed description

This study used Active and placebo as a control to explore the efficacy, safety and pharmacokinetic characteristics of multiple administration of different doses of TRD205 tablets for postoperative analgesia after unilateral total hip replacement surgery

02

Conditions studied

  • Postoperative Analgesia After Unilateral Hip Arthroplasty
03

In context

Lead sponsor

Beijing Tide Pharmaceutical Co., Ltd is the lead sponsor of 14 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written
  • Age 18 to 80 years, inclusive
  • 18-32 kg/m²
  • I-II
  • Scheduled for elective unilateral total hip arthroplasty under general anesthesia
  • Able to understand study procedures and pain rating scales

Exclusion criteria

Exclusion Criteria:

  • to TRD205, celecoxib, or study-related medications
  • Use of prohibited analgesics, sedatives, inhibitors/inducers, or analgesic herbs within specified
  • Inability to take oral medications postoperatively
  • Ipsilateral hip surgery within 1 year; contralateral hip surgery within 1 month
  • Hip revision surgery, developmental dysplasia Crowe type IV, or tumor involving hip
  • hemodynamic instability or cardiac arrhythmia
  • Severe hepatic, renal, cardiovascular, or metabolic disease
  • History of NSAID-induced asthma, active peptic ulcer disease
  • Drug or alcohol abuse within 1 year
  • Pregnancy, breastfeeding, or lack of effective
  • Participation in another interventional clinical trial within 3 months
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    200mg treatment group

    TRD205 Tablets (Low Dose)

    Drug: TRD205 Tablets, oral; 400 mg initial dose, then 200 mg q12h for 3 doses; total 4 doses

  • Experimental
    400mg treatment group

    TRD205 Tablets (Middle Dose)

    Drug: TRD205 Tablets, oral; 800 mg initial dose, then 400 mg q12h; total 4 doses

  • Experimental
    600mg treatment group

    TRD205 Tablets (High Dose)

    Drug: TRD205 Tablets, oral; 1200 mg initial dose, then 600 mg q12h; total 4 doses

  • Active comparator
    Active Control (Celecoxib)

    Celecoxib Capsules

    Drug: Celecoxib, oral; 400 mg initial dose, then 200 mg q12h; total 4 doses

  • Placebo comparator
    Placebo Control

    Placebo for TRD205 and Celecoxib

    Drug: Matching placebo tablets and capsules, same dosing schedule

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the pain intensity-time curve (AUC0-48h) of resting pain NRS from 0 to 48 hours after surgery

    Time frame: 0 to 48 hours after surgery

Secondary outcomes

  1. AUC of resting pain NRS at 0-4, 0-6, 0-12, 0-24, 24-48 hours postoperatively

    Time frame: 0-4, 0-6, 0-12, 0-24, 24-48 hours postoperatively

  2. AUC of movement pain NRS at 0-4, 0-6, 0-12, 0-24, 24-48 hours postoperatively

    Time frame: 0-4, 0-6, 0-12, 0-24, 24-48 hours postoperatively

  3. Cumulative morphine-equivalent rescue analgesic dose at 0-4, 0-6, 0-12, 0-24, 0-48 hours

    Time frame: 0-4, 0-6, 0-12, 0-24, 0-48 hours after surgery

  4. Time to first rescue analgesia

    Time frame: Within 48 hours after the surgery, the period from the end of the surgery to the first administration of analgesic medication for relief purposes

  5. Number and proportion of participants using rescue analgesia

    Time frame: 0-48 hours postoperatively

  6. Participant and investigator satisfaction with analgesia with the 5-point scale,the score range from 0 to 4, where 0 indicates poor, 1 indicates average, 2 indicates good, 3 indicates very good, and 4 indicates excellent.

    At 48 hours after the surgery, the participants and the research doctors respectively evaluated the overall pain relief satisfaction of the test drug used on a 5-point scale, with the score range from 0 to 4, where 0 indicates poor, 1 indicates average, 2 indicates good, 3 indicates very good, and 4 indicates excellent.

    Time frame: 48 hours postoperatively

  7. By evaluating security metrics such as AEs, SAEs and TEAEs to evaluate the safety of multiple administration of TRD205 tablets in patients with postoperative analgesia after unilateral hip arthroplasty.

    Time frame: 5 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jun 2026, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 22, 2026
StartActual
Mar 18, 2026
Primary completionEst.
Jun 27, 2026
CompletionEst.
Jul 27, 2026
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07543796
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Mar 18, 2026
Primary completion
Jun 27, 2026 (estimated)
Completion
Jul 27, 2026 (estimated)
Last update
Apr 22, 2026

Study contacts

xiaohong zhang Beijing Tide Pharmaceutical Co., Ltd
Contact
zhangxh3@tidepharm.com
86-10-6788-0648-5064

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRD205

Start the discussion